Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560814 | 1.00 | VNN1 (0.42) | VNN1ALDH1A1MAPTPARP14FFAR1 | |
| SCHEMBL16294920 | 0.84 | CA1 (0.46) | ALDH1A1 | |
| SCHEMBL16295803 | 0.84 | EGFR (0.40) | ALDH1A1FFAR1FFAR4MAPK8 | |
| SCHEMBL30560864 | 0.84 | EGFR (0.40) | ALDH1A1FFAR1FFAR4MAPK8 | |
| SCHEMBL30560879 | 0.81 | NR4A2 (0.45) | ALDH1A1MAPTFFAR1FFAR4MAPK8 | |
| SCHEMBL16296156 | 0.81 | NR4A2 (0.45) | ALDH1A1MAPTFFAR1FFAR4MAPK8 | |
| SCHEMBL16294923 | 0.78 | KDM4E (0.38) | ALDH1A1MAPTFFAR1BRS3ALKBH1 | |
| SCHEMBL30082014 | 0.78 | KDM4E (0.38) | ALDH1A1MAPTFFAR1BRS3ALKBH1 | |
| SCHEMBL16295784 | 0.78 | NAMPT (0.43) | — | |
| SCHEMBL2825943 | 0.76 | HTT (0.47) | ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | claimed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | claimed |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ANTABIO SAS (FR) | 2016-09-22 | — | — | US | claimed |
| EP-3008045-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | Antabio SAS (FR) | 2016-04-20 | — | — | EP | claimed |
| WO-2014198849-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2014-12-18 | — | — | WO | claimed |
| US-12378244-B2 | Diazabicyclooctanones as inhibitors of serine β-lactamases | ANTABIO SAS (FR) | 2025-08-05 | — | — | US | disclosed |
| US-20240391919-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2024-11-28 | — | — | US | disclosed |
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | ANTABIO SAS (FR) | 2024-02-20 | — | — | US | disclosed |
| CN-117384155-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4272831-A2 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | Antabio SAS (FR) | 2023-11-08 | — | — | EP | disclosed |
| CN-111954671-B | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-3833665-B1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2023-07-19 | — | — | EP | disclosed |
| EP-3833665-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | Antabio SAS (FR) | 2021-06-16 | — | — | EP | disclosed |
| CN-111954671-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2020-11-17 | — | — | CN | disclosed |
| WO-2020030761-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2020-02-13 | — | — | WO | disclosed |
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | disclosed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | disclosed |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ANTABIO SAS (FR) | 2016-09-22 | — | — | US | disclosed |
| EP-3008045-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | Antabio SAS (FR) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014198849-A1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | STS, BCKDK, PEPD | VNN1 745/4885ALDH1A1 650/4885MAPT 4602/4885 |
| US-20240391919-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | STS, BCKDK, PEPD | VNN1 745/4885ALDH1A1 650/4885MAPT 4602/4885 |
| US-12378244-B2 | Diazabicyclooctanones as inhibitors of serine β-lactamases | STS, PEPD, BCKDK | VNN1 728/4885ALDH1A1 669/4885MAPT 4625/4885 |
| US-20160272601-A1 | Antibacterial Thiazolecarboxylic Acids | ME1, TALDO1, COASY | VNN1 733/4885ALDH1A1 40/4885MAPT 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.